NCT01346072View on ClinicalTrials.gov

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2014

Conditions
Cardiovascular DiseasesHeart DiseasesHeart Failure
Interventions
DRUG

tolvaptan

oral, 30 mg, single dose, one time administration

Trial Locations (1)

27514

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER